Last updated: 2026-10-13 10:26:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Sol-Gel Technologies Ltd. (SLGL) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $71,13, with a market capitalisation of $234,97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $28,81 to $97,97. This page covers its latest market performance, valuation, price trends and company information.
$234,97M | |
$71,05 | |
$210,00 | |
$3,34 | |
$72,40 | |
1,00 | |
55,87K | |
-- | |
$97,97 | |
$28,81 | |
-- | |
-- |
Sol-Gel Technologies Ltd. (SLGL) is trading at $71,13 in pre-market trading as of 2026-10-13 08:02:00, down 1,75% ($1,27) from the previous close of $72,40
Pre-market trading shows how investors are pricing SLGL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Sol-Gel Technologies Ltd. (SLGL) moved from $72,00 to $71,13, representing a decline of 1,20% ($0,87).
The stock traded between $66,52 and $79,50 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 35,77 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 61,2%
SLGL is currently trading at $71,13, placing it 61,2% of the way from its 52-week low of $28,81 to its 52-week high of $97,97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sol-Gel Technologies Ltd. (SLGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.